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r Y. Joseph Woo (Philadelphia, Pa). Does the WIF block the
anonical and noncanonical Wnts or one group in particular?
Dr Kim. That is a good question. On the basis of our Western
nalysis, it seems that there is some inhibition of the canonical
athway because there is some decrease in -catenin levels. We
ave looked at disheveled levels as a marker of noncanonical
athways, and our results thus far have been mixed. It seems that
n some of the cell lines we have tested, disheveled levels are
ecreased, but in others they stay the same.
Dr Robert J. Cerfolio (Birmingham, Ala). Excellent work.
ongratulations. Now, please take me on your Disney World ride
f the future 3 years, 5 years, 7 years from now. Tell me how you
nvision your data helping us treat patients in the land of tomor-
ow. Is it a targeted therapy with radiotherapy, is it a targeted
herapy with adjuvant chemotherapy, neoadjuvant therapy? How
o you see this affecting patient care 10 years from now?
Dr Kim. That is a great question. I think WIF is a good target
or therapy because it acts in the extracellular space. Therefore a
ot of problems of intracellular delivery can be avoided. However,
hat I did not show you was that the protein concentrations that
e required to actually have an effect were really quite high.
herefore I do not think that recombinant WIF by itself could be
sed as a therapy. We have some other experiments that seem to
ndicate there is some kind of an autocrine effect, as well as a
aracrine effect. I think that future avenues could be something
long the lines of a fusion protein or some type of protein that has
he active moiety along with some other delivery molecule.
Dr Mark J. Krasna (Baltimore, Md). Dr Kim, Dr Byrne and
are curious. What does Wnt stand for, or after whom is it named?
Dr Kim. As I alluded to, the Wnt pathway is a key pathway in
evelopment, and it is named after a combination of the wingless
ene of Drosophila because mutations lead to wing malformation
nd the Int gene in mice, the integration site for the mouse
ammary tumor virus.
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